Search

Your search keyword '"Evelyne Marry"' showing total 2 results
Start Over Author "Evelyne Marry" Publisher springer science and business media llc
2 results on '"Evelyne Marry"'

1. Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)

Author

Catherine Faucher, Jean-Baptiste Thibert, John De Vos, Christine Giraud, Caroline Ballot, Valérie Mialou, Irina Ionescu, Marie-Thérèse Rubio, Bernard Dazey, Virginie Persoons, Eliane Gluckman, Chantal Kenzey, Jean-Hugues Dalle, Jérôme Larghero, Annalisa Ruggeri, Gérard Michel, Audrey Cras, Fernanda Volt, Jacques-Olivier Bay, Federico Garnier, Evelyne Marry, Vanderson Rocha, Fabienne Pouthier, Christian Chabannon, Hanadi Rafii, Eric Gautier, Danièle Bensoussan, Recherche clinique appliquée à l'hématologie ((EA_3518)), Université Paris Diderot - Paris 7 (UPD7), Centre Scientifique de Monaco (CSM), Agence de la biomédecine [Saint-Denis la Plaine], IRCCS San Raffaele Scientific Institute [Milan, Italie], Etablissement français du sang - Normandie (EFS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] (EFS Bordeaux Nouvelle Aquitaine), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Etablissement Français du Sang Ile de France (EFS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Henry Mondor, Etablissement français du sang [Poitiers] (EFS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Etablissement français du sang- Rhône-Alpes [Lyon], Etablissement Français du Sang [Grenoble] (EFS), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Etablissement français du sang [Rennes] (EFS Bretagne), Hôpital Robert Debré Paris, Hôpital Robert Debré, Hôpital de la Timone [CHU - APHM] (TIMONE), Universidade de São Paulo = University of São Paulo (USP), CHU Clermont-Ferrand, Service d'Hématologie [CHRU Nancy], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, Bone marrow transplant, Multivariate analysis, [SDV]Life Sciences [q-bio], Umbilical cord, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Biomedicine, Bone Marrow Transplantation, Transplantation, Neutrophil Engraftment, business.industry, Network on, Hematopoietic Stem Cell Transplantation, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Hematology, Fetal Blood, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cord blood, Blood Banks, Cord Blood Stem Cell Transplantation, business, 030215 immunology
Abstract

The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 × 107 TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7–90.7) and 79.3% (72.6–86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5–35.1) and 34.3% (27.0–43.5). OS was 49% ± 4 in malignant and 62% ± 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.

Published
2021
Full Text
View/download PDF

2. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

John A. Snowden, Riccardo Saccardi, Kim Orchard, Per Ljungman, Rafael F. Duarte, Myriam Labopin, Eoin McGrath, Nigel Brook, Carmen Ruiz de Elvira, Debra Gordon, Hélène A. Poirel, Francis Ayuk, Yves Beguin, Francesca Bonifazi, Alois Gratwohl, Noel Milpied, John Moore, Jakob Passweg, J. Douglas Rizzo, Stephen R. Spellman, Jorge Sierra, Carlos Solano, Fermin Sanchez-Guijo, Nina Worel, Andreu Gusi, Gillian Adams, Theodor Balan, Helen Baldomero, Gilles Macq, Evelyne Marry, Florence Mesnil, Elena Oldani, Rachel Pearce, Julia Perry, Nicole Raus, Urs Schanz, Steven Tran, Leonie Wilcox, Grzegorz W. Basak, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Jürgen Kuball, Mohamad Mohty, Arjan Lankester, Sylvia Montoto, Arnon Nagler, Jan Styczynski, Ibrahim Yakoub-Agha, Regis Peffault de Latour, Nicolaus Kroeger, Ronald Brand, Liesbeth C. de Wreede, Erik van Zwet, and Hein Putter

Subjects
Haematological cancer, Transplantation, Haematopoietic stem cells, Australia, Hematopoietic Stem Cell Transplantation, Correction, Hematology, United Kingdom, Accreditation, Europe, Benchmarking, Belgium, Italy, Bone Marrow, Spain, Germany, Humans, France, Switzerland
Abstract

In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results